The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults
Abstract
Background The diagnosis of growth hormone (GH) deficiency in adults is based on provocative testing of GH secretion. The insulin tolerance test (ITT), currently the favoured test for this diagnosis, has been criticised for poor reproducibility and inconvenience. Since the combined administration of GH-releasing hormone (GHRH) plus GH-releasing peptide-6 (GHRP-6) is the most potent stimulus of GH secretion, we did a multicentre study comparing GH peaks elicited by ITT with those elicited by the GHRH/GHRP-6 test in healthy controls and GH-deficient individuals (cases). Methods 125 adult patients with organic pituitary disease and 125 healthy individuals were studied. All cases and controls were given GHRH 1 microg per kg bodyweight intravenously plus GHRP-6 1 microg per kg intravenously at 0 min and blood samples were obtained during a subsequent 120 min period. 27 controls and all cases had an ITT. Inclusion criteria were severe GH deficiency--ie, a GH peak after ITT of Findings GH peaks seen after the GHRH/GHRP-6 test did not result in any side-effects and were not affected by age, sex, amount of adipose tissue, or by the GH assay system used. The GH mean peak after the GHRH/GHRP-6 test was 59.2 microg/L (SD 2.2) for controls and 4.1 microg/L (0.3) for cases, whereas after ITT the mean peak was 14.3 microg/L (1.7) and 0.5 microg/L (0.06), respectively. The differential peak responses of controls and cases was greater (p or = 20.00 microg/L be considered normal and Interpreta…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another potent and validated provocative test is the GHRHϩGHRP-6 test (224, 225).It has a BMI-dependent cutoff (15 and 5 g/L for lean and obese subjects with BMI Ͼ 35 kg/m 2 , respectively) and possesses great accuracy in distinguishing normal subjects from patients with GHD (224, 225).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [225]
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
Hanley, J. A., & McNeil, B. J. (1982) · Radiology · doi:10.1148/radiology.143.1.7063747 · Cited by 21,856
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K. (1999) · Nature · doi:10.1038/45230 · Cited by 8,479
Problems of Spectrum and Bias in Evaluating the Efficacy of Diagnostic Tests
Ransohoff, D. F., & Feinstein, A. R. (1978) · New England Journal of Medicine · doi:10.1056/nejm197810262991705 · Cited by 1,734
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
BENEFICIAL EFFECTS OF GROWTH HORMONE TREATMENT IN GH-DEFICIENT ADULTS
Jørgensen, J. O. L., Thuesen, L., Ingemann-Hansen, T., Pedersen, S. A., Jørgensen, I., Skakkebaek, N. E., & Christiansen, J. S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92328-3 · Cited by 890
Clinical Aspects of Growth Hormone Deficiency in Adults
BOER, H. D., BLOK, G.-J., & DER VEEN, E. A. V. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-63 · Cited by 723
; (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.2.379 · Cited by 655
Effects of Estrogen and Sex Difference on Secretion of Human Growth Hormone1
FRANTZ, A. G., & RABKIN, M. T. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-11-1470 · Cited by 467
The Diagnosis of Growth Hormone Deficiency in Adults
Ho, K. K. Y., & Hoffman, D. M. (1997) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.6.suppl10_35 · Cited by 428
Research works printed but not linked: 1
- Popovic, 1995, J Clin Endocrinol Metab, 80, 942
Cited by
Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
van der Lely, A. J., Tschöp, M., Heiman, M. L., & Ghigo, E. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0029 · Cited by 1,187
“The gastric hormone ghrelin was identified as an endogenous ligand for the former orphan receptor GHS-R 1a (1, 13, 14); the discovery of this receptor followed by 20 yr that of synthetic GHS, which specifically binds it (1, 14, 17, 19–21, Abbreviations: AGRP, Agouti-related protein; CNS, central nervous system; CST, c…”
MethodInfluentialMüller, T. D., Nogueiras, R., Andermann, M. L., Andrews, Z. B., Anker, S. D., Argente, J., Batterham, R. L., Benoit, S. C., Bowers, C. Y., Broglio, F., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.03.005 · Cited by 1,034
“Furthermore, ghrelin mimetics have been investigated as diagnostic agents to establish growth hormone deficiency [107] as well as a therapeutic option for age-dependent GH decline and have yielded some potentially beneficial effects [80] (Table 1).”
Self-citationGhrelin?a hormone with multiple functions
KORBONITS, M. (2004) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2004.03.002 · Cited by 595
Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency
Biller, B. M. K., Samuels, M. H., Zagar, A., Cook, D. M., Arafah, B. M., Bonert, V., Stavrou, S., Kleinberg, D. L., Chipman, J. J., & Hartman, M. L. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8509 · Cited by 423
“Subsequent studies will be needed to confirm these promising initial findings and to evaluate the proposed cut-points, which are higher than with ITT (14, 56, 57).”
BackgroundNeuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity
Muccioli, G., Tschöp, M., Papotti, M., Deghenghi, R., Heiman, M., & Ghigo, E. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01432-2 · Cited by 385
Metadata
- Authors
- Popovic, V., Leal, A., Micic, D., Koppeschaar, H. P., Torres, E., Paramo, C., Obradovic, S., Dieguez, C., & Casanueva, F. F.
- Affiliations
- Hospital Universitario Virgen del Rocío (ES)
- Universidade de Santiago de Compostela (ES)
- Corresponding author
- Casanueva, Felipe F
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2000-09
- Volume
- 356
- Issue
- 9236
- Pages
- 1137-1142
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2155790795
- Semantic Scholar
- 17892356dd55befde98c2645990a0fa6d8dd4754
- Cited by
- 185
- References
- 33
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 1 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 1 · 2017: 2 · 2016: 5 · 2015: 10 · 2014: 5 · 2013: 6 · 2012: 10
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Xunta de Galicia
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Keywords
- growth hormone deficiency, adults, growth hormone-releasing hormone, insulin tolerance test, provocation tests, diagnostic thresholds, pituitary disorders, receiver operating characteristic, test reproducibility, age and sex effects, adipose tissue
- MeSH terms
- Adolescent, Adult, Aged, Child, Female, Humans, Insulin, Male, Middle Aged, Oligopeptides, Pituitary Diseases, ROC Curve, Sensitivity and Specificity, Growth Hormone-Releasing Hormone, Body Mass Index, Case-Control Studies, Human Growth Hormone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. https://app.cochat.ai/papers/10.1016/s0140-6736(00)02755-0
- The paper
- Popovic, V., Leal, A., Micic, D., Koppeschaar, H. P., Torres, E., Paramo, C., Obradovic, S., Dieguez, C., & Casanueva, F. F. (2000). GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. The Lancet. https://doi.org/10.1016/s0140-6736(00)02755-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.